Vitamin D-Binding Protein Is a Potential Urinary Biomarker of Irbesartan Treatment Response in Patients with IgA Nephropathy.
Vitamin D-Binding Protein Is a Potential Urinary Biomarker of Irbesartan Treatment Response in Patients with IgA Nephropathy.
复制标题
DOI：
10.1089/gtmb.2016.0070
复制
发表时间：
2016-11
影响因子：
1.4
通讯作者：
Jiashun Zeng;Q. Wen;R. Rong;F. Huang;Qiongqiong Yang;Xueqing Tang;Feng He;N. Huang;Xueqing Yu
中科院分区：
文献类型：
--
作者：
Jiashun Zeng;Q. Wen;R. Rong;F. Huang;Qiongqiong Yang;Xueqing Tang;Feng He;N. Huang;Xueqing Yu
本研究的目的是确定预测免疫球蛋白A肾病（IgAN）患者厄贝沙坦（血管紧张素受体阻滞剂）治疗反应的标志物。方法收集IgAN患者厄贝沙坦治疗前后的尿液标本，并与健康志愿者的尿液进行比较。测定24 h尿蛋白总量以确定治疗反应。采用双向凝胶电泳结合基质辅助激光解吸电离飞行时间串联质谱（MALDI-TOF-MS/MS）技术对尿蛋白质组进行分析。Western blotting用于验证蛋白表达。采用受试者工作特征曲线评价候选生物标志物的敏感性和特异性。结果4个差异表达蛋白被鉴定为维生素D结合蛋白（VDPs）。免疫印迹显示，尿VDPs在无反应与有反应的IgAN患者中显著升高。尿VDP作为预测IgAN患者厄贝沙坦无反应性的生物标志物的敏感性、特异性和准确性分别为65%、85%和75%。结论尿VDP可作为预测厄贝沙坦治疗反应的生物标志物。
AIMS The purpose of this study was to identify predictive markers of irbesartan (an angiotensin receptor blocker) treatment response in immunoglobulin A nephropathy (IgAN) patients. METHODS Urine samples were collected both before and after irbesartan treatment in IgAN patients and compared with urine from healthy volunteers. The total urinary protein produced in 24 h was measured to determine therapeutic response. The urinary proteome was evaluated by two-dimensional gel electrophoresis coupled with MALDI-TOF-MS/MS analysis. Western blotting was used to verify protein expression. A receiver operating characteristic curve was used to evaluate the sensitivity and specificity of candidate biomarkers. RESULTS Four differentially expressed proteins were identified as vitamin D-binding proteins (VDPs). Western blot showed that urinary VDPs were significantly elevated in nonresponsive versus responsive IgAN patients. The sensitivity, specificity, and accuracy of urinary VDP as a predictive biomarker of irbesartan nonresponsiveness in IgAN were 65%, 85%, and 75%, respectively. CONCLUSION Our results revealed that urinary VDP might be a useful biomarker for predicting irbesartan treatment response.